Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Newron Pharmaceuticals SpA's
Operating Income
for the
six
months ended in Dec. 2025 was CHF-5.64 Mil. Newron Pharmaceuticals SpA's Interest Expense for the
six
months ended in Dec. 2025 was CHF-2.03 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Newron Pharmaceuticals SpA's Interest Coverage or its related term are showing as below:
XSWX:NWRN's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Newron Pharmaceuticals SpA Interest Coverage Related Terms
Newron Pharmaceuticals SpA Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:NWRN vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newron Pharmaceuticals SpA Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Newron Pharmaceuticals SpA's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Newron Pharmaceuticals SpA did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Newron Pharmaceuticals SpA (XSWX:NWRN) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Newron Pharmaceuticals SpA and its competitors. According to the industry distribution chart, Newron Pharmaceuticals SpA ranks #999999 out of 377 companies in the Biotechnology industry.
Is Newron Pharmaceuticals SpA's Interest Coverage too high?
Newron Pharmaceuticals SpA's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Newron Pharmaceuticals SpA ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Newron Pharmaceuticals SpA ranks #999999 out of 377 companies for Interest Coverage. This places Newron Pharmaceuticals SpA in the lower half of its industry. The industry median Interest Coverage is 106.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Newron Pharmaceuticals SpA and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newron Pharmaceuticals SpA's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XSWX:NWRN) is currently considered Fairly Valued. The stock's GF Value™ is CHF12.92, compared to a current price of CHF12.64 — trading 2.2% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Newron Pharmaceuticals SpA's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XSWX:NWRN), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued.
The current stock price of CHF12.64 is trading 2.2% below its estimated GF Value™ of CHF12.92.
GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.
Key valuation signals for XSWX:NWRN:
Interest Coverage: 0 (At Loss)
GF Value™: CHF12.92 vs. price of CHF12.64 (2.2% below fair value)
No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
62GF Score
Get the complete analysis for XSWX:NWRN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NWRN has been successfully added to your 
